CATX
What one share of Perspective Therapeutics holds
Pharmaceutical Preparations
We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Perspective Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.25 |
|---|---|
| Capex (buildings and equipment) | $0.30 |
| Free cash flow | −$1.30 |
| Cash and investments | $0.42 |
| Debt | $0.01 |
| Book value | $2.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | $0.87 | −$1.12 | $0.10 | −$1.14 | — | $1.93 |
| 2018 | $1.07 | −$1.21 | $0.06 | −$1.10 | — | $0.89 |
| 2019 | $1.09 | −$0.80 | $0.07 | −$0.82 | — | $1.14 |
| 2020 | $1.43 | −$0.51 | $0.04 | −$0.58 | — | $0.83 |
| 2021 | $0.97 | −$0.30 | $0.04 | −$0.31 | — | $4.75 |
| 2022 | $0.76 | −$0.51 | $0.02 | −$0.56 | — | $4.31 |
| 2022 | $0.00 | −$0.76 | $0.02 | −$0.75 | — | $3.85 |
| 2023 | $0.05 | −$1.74 | $0.04 | −$1.42 | — | $2.67 |
| 2024 | — | −$1.23 | $0.84 | −$1.13 | — | $4.11 |
| 2025 | — | −$1.40 | $0.17 | −$1.29 | — | $2.79 |